These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 25695403)

  • 1. CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.
    Rennard SI; Dale DC; Donohue JF; Kanniess F; Magnussen H; Sutherland ER; Watz H; Lu S; Stryszak P; Rosenberg E; Staudinger H
    Am J Respir Crit Care Med; 2015 May; 191(9):1001-11. PubMed ID: 25695403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.
    Kirsten AM; Förster K; Radeczky E; Linnhoff A; Balint B; Watz H; Wray H; Salkeld L; Cullberg M; Larsson B
    Pulm Pharmacol Ther; 2015 Apr; 31():36-41. PubMed ID: 25681277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
    Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
    Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral immunity and delayed-type hypersensitivity in healthy subjects treated for 30 days with MK-7123, a selective CXCR2 antagonist.
    Seiberling M; Kamtchoua T; Stryszak P; Ma X; Langdon RB; Khalilieh S
    Int Immunopharmacol; 2013 Oct; 17(2):178-83. PubMed ID: 23791619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of the CXCR2 antagonist, MK-7123, on bone marrow functions in healthy subjects.
    Hastrup N; Khalilieh S; Dale DC; Hanson LG; Magnusson P; Tzontcheva A; Tseng J; Huyck S; Rosenberg E; Krogsgaard K
    Cytokine; 2015 Apr; 72(2):197-203. PubMed ID: 25661195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD.
    Abrahams R; Moroni-Zentgraf P; Ramsdell J; Schmidt H; Joseph E; Karpel J
    Respir Med; 2013 Jun; 107(6):854-62. PubMed ID: 23490224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
    Kuna P; Jenkins M; O'Brien CD; Fahy WA
    Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations.
    Seemungal TA; Wilkinson TM; Hurst JR; Perera WR; Sapsford RJ; Wedzicha JA
    Am J Respir Crit Care Med; 2008 Dec; 178(11):1139-47. PubMed ID: 18723437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.
    Calverley PM; Sanchez-Toril F; McIvor A; Teichmann P; Bredenbroeker D; Fabbri LM
    Am J Respir Crit Care Med; 2007 Jul; 176(2):154-61. PubMed ID: 17463412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis.
    Donohue JF; Kerwin E; Barnes CN; Moran EJ; Haumann B; Crater GD
    BMC Pulm Med; 2020 May; 20(1):134. PubMed ID: 32393215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
    Brightling CE; Bleecker ER; Panettieri RA; Bafadhel M; She D; Ward CK; Xu X; Birrell C; van der Merwe R
    Lancet Respir Med; 2014 Nov; 2(11):891-901. PubMed ID: 25208464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
    Donohue JF; Fogarty C; Lötvall J; Mahler DA; Worth H; Yorgancioglu A; Iqbal A; Swales J; Owen R; Higgins M; Kramer B;
    Am J Respir Crit Care Med; 2010 Jul; 182(2):155-62. PubMed ID: 20463178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.
    Decramer ML; Chapman KR; Dahl R; Frith P; Devouassoux G; Fritscher C; Cameron R; Shoaib M; Lawrence D; Young D; McBryan D;
    Lancet Respir Med; 2013 Sep; 1(7):524-33. PubMed ID: 24461613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease.
    Bernstein JA; Liu N; Knorr BA; Smugar SS; Hanley WD; Reiss TF; Greenberg S
    Respir Med; 2011 Mar; 105(3):392-401. PubMed ID: 20970976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease.
    Barnes NC; Qiu YS; Pavord ID; Parker D; Davis PA; Zhu J; Johnson M; Thomson NC; Jeffery PK;
    Am J Respir Crit Care Med; 2006 Apr; 173(7):736-43. PubMed ID: 16424444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
    Donohue JF; Maleki-Yazdi MR; Kilbride S; Mehta R; Kalberg C; Church A
    Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
    Decramer M; Anzueto A; Kerwin E; Kaelin T; Richard N; Crater G; Tabberer M; Harris S; Church A
    Lancet Respir Med; 2014 Jun; 2(6):472-86. PubMed ID: 24835833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease.
    Zhong N; Zheng J; Wen F; Yang L; Chen P; Xiu Q; Yao W; Sun T; Zhao Z; Shen H; Shi Y; Lin J; Li Q
    Curr Med Res Opin; 2012 Feb; 28(2):257-65. PubMed ID: 22046961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.